Table 3.
Recently reported nanoparticles studies since 2015.
| Formulation Type |
Drug/API | Polymer | Advantages | Route of Administration |
References |
|---|---|---|---|---|---|
| Nanoparticle | Rotigotine | Maleimide-PEG -D,L-PLGA (M.w 3400–20,000 Da) and methoxy-PEG-D,L-PLGA (M.w 2000–20,000 Da) | A higher concentration of rotigotine was observed in the striatum with release up to 48 h | Intranasal | [113] |
| Nanoparticle imprinted film | Selegiline | D,L-PLGA, Ethylene-vinyl acetate | In-vivo drug release for more than 72 h was observed from the film | Transdermal | [117] |
| Nanoparticle | L-DOPA methyl ester/benserazide | D,L-PLGA50:50 (M.w 47,000 Da), PLA (M.w 83,000 Da) | The prepared formulation reduced the L-DOPA-induced dyskinesia in the dyskinetic rats | Subcutaneous | [118] |
| Nanoparticle | Pramipexole 2HCL |
Chitosan (>90% deacetylation) | In-vivo and ex-vivo diffusion showed complete drug release in 24 h. Reduced motor deficit in nanoparticle-treated group compared to nasal solution and oral tablet |
Intranasal | [119] |
| Nanospheres | VEGF | D,L-PLGA | VEGF encapsulated in the nanosphere could cross the BBB and showed a strong neuroprotective effect | Intravenous | [120] |
| Nanoparticle (Device) |
DA | Cellulose acetate phthalate (M.w 49,000 Da) | DA was released for 30 days with a higher concentration in CSF than in plasma, which reduced the side effects of DA | Intracranial | [121] |
| Polysorbate 80 coated nanoparticle | Ropinirole HCL | Chitosan (M.w 150,000 Da) | In-vitro drug release up to 10 h was observed. In-vivo studies revealed the higher concentration of ropinirole in the brain over other highly perfused organs | Intravenous | [122] |